The Noxofarm Ltd (ASX: NOX) share price soared after positive results regarding its cancer treatment drug, Veyonda, were released this morning. The immuno-oncology drug development company saw its share price rise 12% to 37 cents on the news. Noxofarm shares have since been sold down to 34 cents (at the time of writing) representing a more modest gain of 3% for the day so far.

While this is good news for the company, the drug is still a very long way off commercialisation stage. If Veyonda does actually reach commercialisation, it’s likely the Noxopharm share price will once again surge. Currently, however, Noxopharm continues consuming cash via capital raisings. The company’s share price has been gradually shrinking over the past couple of years due to the ballooning number of shares on issue. Noxopharm has already undertaken two equity raises this year.

What does Noxopharm do?

Noxopharm is an ASX listed, clinical stage drug development company. Noxopharm’s current clinical stage drug is Veyonda. Veyonda aims to work with the body to fight cancer, not against it as is commonplace. It enhances the cancer-killing effect of standard chemotherapy and radiotherapy. Thus, enabling lower doses of these toxic therapies to be successfully administered. Furthermore, the drug seeks to activate the body’s innate immune cell function to attack those cancer cells that have survived the initial treatment.

Why did the Noxopharm share price soar?

The Noxopharm share price soared as it was announced that independent data confirmed Idronoxil could convert ‘cold’ tumours to ‘hot’ tumours. Idronoxil is the main active ingredient in Veyonda. This action is regarded as a fundamental goal in enabling immuno-oncology drugs. These drugs have long been hailed as the future of cancer therapy, but are poorly effective in ‘cold’ tumours. ‘Cold’ tumours are the majority of those found in human cancer patients. The ability to convert tumours to ‘hot’ restores cancer-fighting immune cells to tumours. Therefore enabling the body to aid in the fight against cancer.

This conversion is seen as a prerequisite in expanding the annual US$20 billion immuno-oncology drug market. Furthermore, a patent has been lodged on this potentially highly valuable intellectual property with Noxopharm to commence discussions with global oncology firms.

What now for the Noxopharm share price?

Despite this encouraging news, the data is only pre-clinical and, as such, the drug is still a long way from being released to the markets. Nevertheless, it is much needed good news for the ASX biotech stock. The Noxopharm share price has seen its share price spike 100% so far in July despite this being the first piece of news announced this month.

More reading

• 2 quality ASX 200 shares to buy and hold beyond 2027
• How to invest $10,000 in ASX 200 shares for growth and dividends
• Why Catapult, Eclipx, FlexiGroup, & Whispir shares are charging higher
• The Coles share price is flying under the radar
• Why CSR, South32, Sydney Airport, & Webjet shares are tumbling lower

Motley Fool contributor Daniel Ewing has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post Noxopharm share price soars 12% higher on drug update appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/30uAgB4

In afternoon trade the S&P/ASX 200 Index (ASX: XJO) looks set to start the week with a disappointing decline. At the time of writing the benchmark index is down 0.6% to 5,995.3 points.

Four shares that have not let that hold them back are listed below. Here’s why they are charging higher:

The Catapult Group International Ltd (ASX: CAT) share price has rocketed over 12% higher to $1.43. Investors have been buying the sports analytics and wearables company’s shares following the release of its full year update. According to the release, Catapult generated net free cash of $9 million in FY 2020. This was a massive $24.1 million increase on FY 2019’s result. As a result, it has achieved positive cash flow a year earlier than forecast. This was driven partly by its subscription-based business model.

The Eclipx Group Ltd (ASX: ECX) share price is up 6% to $1.38. This follows the announcement of a binding agreement for the sale of the Right2Drive business to Growth Factor Group for a purchase price of up to $26.5 million. The transaction includes an ongoing commercial relationship with Right2Drive, including a right to supply new vehicle leases to Right2Drive for a period of three years. All existing leases between Eclipx and Right2Drive will also remain on foot.

The FlexiGroup Limited (ASX: FXL) share price is up 3.5% to $1.25. This morning FlexiGroup released an update on its buy now pay later platform, Humm. According to the release, fourth quarter ecommerce volume was up 315%, with total transactions up 447% on the prior corresponding period. This was driven by a record number of ecommerce and instore integrations during the quarter and a new BPAY feature which allows customers to pay for bills in manageable interest. At the end of the quarter, the humm platform had a total of 56,000 retail partners.

The Whispir Ltd (ASX: WSP) share price has surged 17% higher to $3.94 following its fourth quarter update. The communications workflow platform provider’s update revealed strong demand by new and existing customers during the pandemic. According to the release, the company’s annualised recurring revenue rose 4.2% over the March quarter and 35.7% over the prior corresponding period to $42.2 million. This was driven by strong growth in the ANZ and Asia regions.

More reading

• Whispir share price surges 8% to a record high on stellar Q4 update
• FlexiGroup share price jumps 8% higher following BNPL update
• Catapult share price on watch after FY20 Results Preview
• These are the 10 most shorted shares on the ASX
• How to get rich by investing in small cap ASX shares

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of Catapult Group International Ltd and Whispir Ltd. The Motley Fool Australia has recommended Catapult Group International Ltd, FlexiGroup Limited, and Whispir Ltd. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post Why Catapult, Eclipx, FlexiGroup, & Whispir shares are charging higher appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/30yH94C

The Coles Group Ltd (ASX: COL) share price has surged close to 20% in the past 2 months and is currently trading near record highs. So, what is fuelling the company’s share price and is now the time to invest in Coles shares?

Second wave fears fuelling demand

With Melbourne entering a 6-week lockdown period and fears of a second wave of coronavirus cases growing across the country, supermarkets like Coles could see a renewed surge in demand.

Earlier this month, the company was forced to re-impose purchase restrictions in Victoria as panic-buyers raided supermarkets. Coles has since lifted purchase restrictions after reassuring customers that border closures will not disrupt food and grocery supplies.  

How has Coles performed?

In late April, Coles released its 3rd quarter sales update for FY20, which reflected the unprecedented demand seen during the coronavirus pandemic. Coles reported a 12.9% surge in revenue of $9.2 billion for the quarter, whilst also highlighting a 12.4% increase in comparable sales growth.

According to the company, with more Australians confined to living and working from home, household consumption has surged. As a result, Coles saw a significant increase in demand for general groceries, meat, health, and home products.

However, with the surge in demand Coles has also seen an increase in costs. The company has recruited around 12,000 casual team members in order to deal with the surging demand, whilst also spending more money on security and cleaning services.  

The outlook for Coles

As more customers continue to work from home, post-pandemic, Coles expects consumer behaviour and habits to change as well. The company expects consumers in the future to increase the amount they purchase whilst also utilising online shopping for convenience.

Coles saw 14% growth in online sales revenue for the 3rd quarter, despite its home delivery and ‘Click&Collect’ services being temporarily suspended in March. In order to accommodate the change in consumer behaviour, Coles is looking to increase its online capacity in the future.  

Should you buy?

I think it is important for investors to understand that a surge in demand doesn’t automatically translate into a higher share price. The company still has to invest heavily in e-commerce and other services in order to maintain its growth.

However, despite the increase in costs, I think that Coles is well positioned for growth in 2020 and beyond. The company has a strong pipeline of investment opportunities that are designed to improve its supply chain efficiency and cash status. Examples of this is include investing $950 million over 6 years into automated distribution centres, and developing partnerships with global online specialists.

All that being said, I think a prudent strategy would be to wait until after the August reporting season before buying shares in Coles.

More reading

• Coles and 2 more ASX 200 shares to watch this week
• ASX 200 Weekly Wrap: Blue chip shares pull ASX 200 back over 6,000 points
• Buy these strong ASX shares for your retirement portfolio
• 4 ASX shares I’d buy to protect against a recession
• Top ASX dividend shares to buy in July 2020

Motley Fool contributor Nikhil Gangaram has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of COLESGROUP DEF SET. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post The Coles share price is flying under the radar appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/32wBjTP

In afternoon trade the S&P/ASX 200 Index (ASX: XJO) is on course to start the week with a sizeable decline. At the time of writing the benchmark index is down 0.65% to 5,994.5 points.

Four shares that have fallen more than most today are listed below. Here’s why they are tumbling lower:

The CSR Limited (ASX: CSR) share price is down 4.5% to $3.48. Investors have been selling the buildings products company’s shares following the release of a bearish broker note out of Morgan Stanley. Its analysts have downgraded CSR’s shares to an underweight rating and cut the price target on them to $3.10. The broker expects its performance to be impacted by lower activity levels because of the pandemic.

The South32 Ltd (ASX: S32) share price is down 2% to $2.18. Investors have been selling the mining giant’s shares after the release of its fourth quarter update. South32’s update revealed record production at its Brazil Alumina, Hillside Aluminium, and Australia Manganese mines in FY 2020. However, things weren’t quite as positive for its Illawarra metallurgical coal production. It was below guidance for the year due to challenging strata conditions. The company also warned that commodity prices could be lower for an extended period of time.

The Sydney Airport Holdings Pty Ltd (ASX: SYD) share price is down almost 1.5% to $5.40. The airport operator’s shares have come under pressure following the release of its traffic update for June. That update revealed that a total of 172,000 passengers passed through its gates during the month. This was a 94.9% reduction on the prior corresponding period’s ~3.4 million passengers.

The Webjet Limited (ASX: WEB) share price is down 5% to $2.85. Investors have been selling travel shares on Monday amid increasing concerns over the recovery of the domestic travel market. This follows a spike in coronavirus cases in pockets of New South Wales and further cases in Victoria. Given how important these states are for domestic tourism, this could derail the recovery and put pressure on the likes of Webjet.

More reading

• ASX 200 down 0.5%: Sydney Airport and South32 updates, HUB24 delivers record Q4
• Why the South32 share price is falling today
• Sydney Airport share price on watch after traffic update
• ASX 200 Weekly Wrap: Blue chip shares pull ASX 200 back over 6,000 points
• These are the 10 most shorted shares on the ASX

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of and has recommended Webjet Ltd. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post Why CSR, South32, Sydney Airport, & Webjet shares are tumbling lower appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/39jKTuI

The Respiri Ltd (ASX: RSH) share price has today reached 52-weeks highs, following news that the eHealth company signed a merchant services agreement with major payments share Zip Co Ltd (ASX: Z1P). The Respiri share price is currently trading over 17% higher at 17 cents per share.

What does Respiri do?

Respiri is a medical technology company that develops devices and mobile health applications, with the aim of improving patient self-management of chronic, costly respiratory disorders. Respiri’s technology is used in major hospitals in UK, Europe, USA, Japan, Korea and Australia.

The company’s flagship device ‘wheezo’ employs machine learning to provide personalised feedback and education to patients. Its goal is to help improve quality of life for children and adults who suffer from diseases like asthma, diabetes and cardiovascular illness. Furthermore, it aims to dramatically reduce hospital admissions and the economic burden from these diseases.

Respiri’s operations are based in Melbourne, Australia.

Why is the Respiri share price storming higher?

The Respiri share price is climbing on the announcement of a merchant services agreement with well known buy now, pay later (BNPL) service provider, Zip.

Respiri CEO Mr Marjan Mikel noted:”Our Agreement with ZIP provides asthmatic patients seeking access to our platform additional financial flexibility when making these important healthcare decisions relating to improvements in the management of their disease.”

As recently as last Friday, the company also announced that it had signed an exclusive sales agreement with Cipla Australia for wheezo. Cipla Ltd is a globally recognised pharmaceutical company. The deal saw the Respiri share price jump over 30% on Friday alone. 

The agreement with Cipla is for an initial minimum order quantity of 2,000 with delivery in October. It has a 5-year term, with a 3-year renewal option. According to Respiri, Cipla Australia possesses significant sales and marketing infrastructure, covering over 80% of the pharmacy market in Australia.

Foolish takeaway

The Covid-19 crisis has seen a shift toward remote care to try to keep patients out of hospitals, lower costs and improve care. In my view, these factors will encourage greater adoption of Respiri’s remote patient monitors, and the company’s partnerships with Zip and Cipla will also make it easier for consumers to acquire Respiri’s products.

Respiri shares have been storming higher so far this year, as the company sees high demand for its software-as-a-service platform. This demand has seen the Respiri share price rise by more than 70% in 2020.

More reading

• Top brokers name 3 ASX shares to sell next week
• How I’d build a $100,000 ASX portfolio of growth shares
• Why Cann, Flight Centre, Helloworld, & Zip shares are dropping lower
• How to pick an ASX 200 share market bubble
• Why the Zip Co share price sank 11% lower today

Daniel Ewing has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of ZIPCOLTD FPO. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post Respiri share price pops 17% after revealing merchant agreement with Zip appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/30vjult

The S&P/ASX 200 (ASX: XJO) is down over 10% compared to this time a year ago. Individual share performances have varied in the wake of the coronavirus pandemic with some surging and others wilting. 

The shift to eCommerce hastened by the onset of the virus is benefiting online operators. Healthcare companies involved in treatment of coronavirus have also been favored by investors. Meanwhile, gold miners have performed well as investors seek safe haven assets. We take a look at why these nine shares have more than doubled in value over the past year. 

9 ASX shares that have doubled in value over the last year

Australian Ethical Investment Limited (ASX: AEF) 

The Australian Ethical Investment share price is up 210% compared to a year ago. The managed funds and superannuation company invests more than $4 billion for over 57,000 customers in accordance with ethical and sustainability principles. Its Emerging Companies Fund returned 13.9% after all fees in FY20 against a benchmark of negative 7.4%. Australian Ethical Investment earned a performance fee of $3.64 million thanks to the Fund’s outperformance. The company is now expecting underlying profit after tax of between $9 and $9.5 million in FY20, an increase of 41% from FY19. 

Kogan.com Limited (ASX: KGN) 

The Kogan share price has risen 228% over the past year with the online retailer’s performance accelerating during lockdown. Kogan sells a wide range of products from consumer electronics to appliances, homewares, hardware, and toys. During lockdown, demand for homewares and electronics surged, facilitating more time spent living and working from home. Kogan saw gross sales rise more than 100% in April and May. Gross profit grew by more than 130% over the same period. Kogan is benefitting from the ongoing shift to eCommerce which has been hastened by the onset of coronavirus. 

Afterpay Ltd (ASX: APT)

The biggest of the buy now, pay later (BNPL) providers by market capitalisation, the Afterpay share price is up 186% over the past year. Afterpay is benefitting from the move to digital payments, settling record transaction volumes through 4QFY20. Over the full year, Afterpay delivered underlying sales of $11.1 billion, a 112% increase on the previous year. Fourth quarter underlying sales were the highest ever at $3.8 billion, 127% above 4Q FY19. This reflects the accelerating shift to eCommerce which has occurred since the pandemic broke out. The net transaction margin for FY20 is expected to be approximately 2%, underpinning a pathway to longer term profitability for the business. 

Opthea Ltd (ASX: OPT) 

The Opthea share price is up 173% over the past year and has recovered well from the March market correction. The rise in its share price saw Opthea joining the S&P/ASX 300 (XKO) in the most recent quarterly rebalance. Opthea is developing a novel therapeutic to improve vision and reduce retinal swelling in patients with eye diseases. Its product candidate is currently undergoing Phase 2 clinical trials to determine if it improves visual acuity in patients suffering from Wet Age-related Macular Degeneration and Diabetic Macular Edema. The prevalence of both diseases is on the rise due to the aging population and increasing prevalence of diabetes worldwide. 

West African Resources Ltd (ASX: WAF) 

The West African Resources share price has increased nearly 170% since this time a year ago. The company is a gold miner operating in West Africa that has benefitted from the rise in the gold price over recent months. Gold was trading at around $2200 at the start of 2020 but has risen to around $2600 per ounce currently. In the year to 30 June, West African Resources smelted 37,807 ounces of gold and shipped 35,080 ounces. This ASX share reported it held US$65.6 million in cash and gold at 30 June 2020. 

Ramelius Resources Limited (ASX: RMS) 

The Ramelius Resources share price has gained 134% over the past year. Another gold miner to benefit from rising gold prices, Ramelius Resources operates a number of gold projects in Western Australia. The company produced 86,517 ounces of gold in the June quarter and a record 230,426 ounces in FY20. The balance sheet remained robust with cash and gold of $185.5 million and a reduced debt figure of $24.4 million at the end of June. This gives a net cash position of $161.1 million. 

Mesoblast Limited (ASX: MSB) 

The Mesoblast share price has risen 123% in the last year with its cell therapy remestemcel-L proving beneficial in the treatment of seriously ill COVID-19 patients. In April, Mesoblast reported a significant increase in survival for coronavirus patients with acute respiratory distress syndrome (ARDS) who were given the treatment. Remestemcel-L is currently undergoing phase 3 trials to assess its use in adult ARDS patients. During the nine months to the end of March, Mesoblast’s revenues increased 113% reaching US$31.5 million. Loss after tax reduced to US$45.3 million over the period, with cash in hand of US$60 million plus another US$90 million raised in May. 

Codan Limited (ASX: CDA) 

The Codan share price is up 111% over the past year with the company reporting it will deliver a record profit in FY20 of around $63 million. Codan provides communications technology, metal detectors, defence electronics, and mining automation solutions. Customers are humanitarian organisations, mining companies, security and military groups. Demand for metal detectors has remained strong across both recreational and gold mining markets. The communication business has also been performing strongly delivering a $7 million project which led to a record sales month in May. Codan reports it has net cash of $85 million on the balance sheet. 

Fisher & Paykel Healthcare Corp Ltd (ASX: FPH) 

The Fisher & Paykel share price has climbed 115% over the past year with the healthcare company reporting unprecedented demand for its respiratory devices. Production of some hospital hardware products was doubled or tripled earlier this year. Fisher & Paykel announced record results for the year to 31 March 2020 with profit after tax rising 37% to $287.3 million. For the first three months of FY21, hardware sales have continued to accelerate and hospital consumables were tracking at a one third increase. 

More reading

• ASX 200 Weekly Wrap: Blue chip shares pull ASX 200 back over 6,000 points
• Top brokers name 3 ASX shares to buy next week
• 3 five-star ASX shares to buy
• These were the worst performing ASX 200 shares last week
• How I’d build a $100,000 ASX portfolio of growth shares

Kate O’Brien has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of Australian Ethical Investment Ltd. and Kogan.com ltd. The Motley Fool Australia owns shares of AFTERPAY T FPO. The Motley Fool Australia has recommended Australian Ethical Investment Ltd. and Kogan.com ltd. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post Why these 9 ASX shares have doubled in value in the past year appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/39biLK4

At lunch on Monday the S&P/ASX 200 Index (ASX: XJO) has started the week in a disappointing fashion. The benchmark index is currently down 0.5% to 6,003.3 points.

Here’s what has been happening on the market today:

South32 update.

The South32 Ltd (ASX: S32) share price has taken a tumble after the release of its fourth quarter update. South32’s update revealed record production at its Brazil Alumina, Hillside Aluminium, and Australia Manganese mines in FY 2020. However, the mining giant’s Illawarra metallurgical coal production was below guidance. This was attributed to challenging strata conditions during the final quarter.

Sydney Airport traffic update.

The Sydney Airport Holdings Pty Ltd (ASX: SYD) share price is dropping lower on Monday after the release of its traffic update for June. According to the release, a total of 172,000 passengers passed through its gates during the month. This was down 94.9% on the prior corresponding period’s ~3.4 million passengers. This comprised 32,000 international passengers (down 97.6%) and 140,000 domestic passengers (down 93.3%).

HUB24 record quarter.

The HUB24 Ltd (ASX: HUB) share price is pushing higher on Monday after revealing a record performance in the fourth quarter. The investment platform provider recorded a net inflow of $1.1 billion for the quarter, which together with favourable market movements, lifted its funds under administration by 14% or $2.1 billion to $17.2 billion. This means that its average monthly net inflows during FY 2020 was $412 million, up 26% from $326 million per month in FY 2019.

Best and worst ASX 200 shares.

The BlueScope Steel Limited (ASX: BSL) share price is the best performer on the ASX 200 with a 3.5% gain. This morning analysts at Macquarie retained their outperform rating and lifted their price target on the steel maker’s shares to $12.55. The worst performer on the ASX 200 has been the Super Retail Group Ltd (ASX: SUL) share price with a 5% decline. This is despite there being no news out of the retailer today.

More reading

• Why CSR, South32, Sydney Airport, & Webjet shares are tumbling lower
• Why the South32 share price is falling today
• HUB24 share price pushes higher on record Q4 performance
• Is the Xero share price in the buy zone right now?
• Coles and 2 more ASX 200 shares to watch this week

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of Hub24 Ltd. The Motley Fool Australia owns shares of and has recommended Super Retail Group Limited. The Motley Fool Australia has recommended Hub24 Ltd. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post ASX 200 down 0.5%: Sydney Airport and South32 updates, HUB24 delivers record Q4 appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/2OIVTbe